Our mission is opening a digital front door to a new kind of healthcare system, one that provides greater access to high quality, convenient and affordable care. No matter who a person is, where they come from, what they look like, or if they have insurance or not—Hims & Hers connects consumers with licensed medical professionals and enables everyone to seek health and wellness care.

HIMS

Andrew Dudum

Chief Executive Officer

Melissa Baird

Chief Operating Officer

Soleil Boughton

Chief Legal Officer and Corporate Secretary

Yemi Okupe

Chief Financial Officer

Chief Executive Officer And Board Of Director

Alex Bard

Board Of Director

Dr. Toby Cosgrove

M.D. Board Of Director

Kirsten Green

Jules Maltz

David Wells

Lynne Chou O’keefe

Andrea Perez

Ambar Bhattacharyya

Dr. Patrick Carroll

About HIMS

Hims & Hers Health 株価情報 (NYSE: HIMS)

最新ニュース Hims & Hers Health (NYSE:HIMS) 株価情報

HIMS & HERS HEALTH INC

Hims & Hers Health

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health Inc

Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) executives allegedly ignored internal warnings that the company was unprepared to launch its <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">obesity drug Wegovy</a>.
As rival Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound gains momentum, the Danish pharmaceutical giant is grappling with the fallout of those early decisions.
Wegovy, approved in the U.S. in mid-2021, marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46139132/spain-accuses-novo-nordisk-of-covert-advertising-for-prescription-weight-loss-drugs" rel="noreferrer noopener">Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs</a>
But the company has struggled to keep pace with Lilly&#8217;s Zepbound, which has surpassed Wegovy in weekly new prescriptions this year.
Amid concerns over its competitiveness in the weight-loss market, Novo is undergoing a leadership shake-up, including <a target="_blank" href="https://www.benzinga.com/news/management/25/05/45466201/ozempic-maker-novo-nordisk-looks-for-new-chief-jorgensen-steps-down" rel="noreferrer noopener">the recent dismissal</a> of CEO Lars Fruergaard Jorgensen and earlier departures like U.S. chief Doug Langa.
Sources told Reuters that during tense internal meetings, sales and marketing staff warned Langa about launching Wegovy too quickly after FDA approval.
They urged a delay until supply and insurance coverage were more secure. With a <a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">list price of up to $1,300 per month</a>, many patients found the drug unaffordable without insurance, and Novo missed an opportunity to build a more stable launch pad while Lilly&#8217;s market entry was still years away.
However, company leadership in Copenhagen held to conservative sales expectations through 2025, Reuters report highlighted, underestimating the scale of demand driven by the global obesity epidemic. Former employees said Novo had internal indicators pointing to stronger uptake but failed to adjust its strategy accordingly.
The consequences were swift. Wegovy&#8217;s launch was plagued by supply shortages, leaving patients without doses and discouraging new users. The high cost also pushed some patients toward the gray market of compounded drugs.
Novo further faced criticism for pricing Wegovy significantly higher than its diabetes drug Ozempic, while Lilly entered the market with Zepbound at $1,080 and provided steep discounts through its LillyDirect pharmacy.
One former insider claimed that Novo hesitated to offer competitive rebates to pharmacy benefit managers (PBMs), limiting the drug&#8217;s accessibility.
This reluctance hurt relationships with insurers and failed to secure broader coverage, placing Novo at a disadvantage compared to Lilly&#8217;s aggressive pricing and reimbursement strategies.
Recently, Novo Nordisk launched its weight-loss drug Wegovy (semaglutide) in India to <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">compete with Eli Lilly</a>.
Price Action: NVO stock is trading higher by 0.13% to 69.11 at last check Tuesday.
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/07/46192989/mesoblast-targets-accelerated-fda-approval-for-heart-failure-drug-revascor" target="_blank" rel="noreferrer noopener">Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Biotech

Large Cap

News

Health Care

Media

General

Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report

Trading Ideas

BMNR

BitMine Immersion Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 74.2%

Financial giants have made a conspicuous bearish move on Constellation Energy. Our analysis of options history for Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) revealed 17 unusual trades.
Delving into the details, we found 17% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $1,504,487, and 10 were calls, valued at $1,069,836.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $380.0 for Constellation Energy over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Constellation Energy's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Constellation Energy's whale trades within a strike price range from $250.0 to $380.0 in the last 30 days. 
<h3>Constellation Energy 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751382203_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.0</td>
<td>$7.7</td>
<td>$7.95</td>
<td>$270.00</td>
<td>$405.0K</td>
<td align="right">954</td>
<td>1.2K</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$8.0</td>
<td>$7.7</td>
<td>$7.77</td>
<td>$270.00</td>
<td>$321.9K</td>
<td align="right">954</td>
<td>449</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.3</td>
<td>$8.0</td>
<td>$8.34</td>
<td>$270.00</td>
<td>$309.4K</td>
<td align="right">954</td>
<td>1.9K</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$61.4</td>
<td>$60.3</td>
<td>$60.3</td>
<td>$250.00</td>
<td>$301.5K</td>
<td align="right">85</td>
<td>53</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.4</td>
<td>$7.9</td>
<td>$8.23</td>
<td>$270.00</td>
<td>$257.0K</td>
<td align="right">954</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Constellation Energy</h3>
Constellation Energy Corp producer of carbon-free energy and a supplier of energy products and services. The company offers generating capacity that includes nuclear, wind, solar, natural gas, and hydroelectric assets. It sells electricity, natural gas, and other energy-related products and sustainable solutions to various types of customers, including distribution utilities, municipalities, cooperatives, and commercial, industrial, public sector, and residential customers in markets across multiple geographic regions. Its operating segments and reporting units are Mid-Atlantic, Midwest, New York, ERCOT, and Other Power Regions.
Having examined the options trading patterns of Constellation Energy, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Constellation Energy</h3>
<ul>
<li>With a volume of 876,259, the price of CEG is down -4.9% at $306.93. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>What Analysts Are Saying About Constellation Energy</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $343.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Constellation Energy, which currently sits at a price target of $350. 
&#x2A; In a cautious move, an analyst from Raymond James downgraded its rating to Outperform, setting a price target of $326. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Constellation Energy, which currently sits at a price target of $380. 
&#x2A; An analyst from Citigroup downgraded its action to Neutral with a price target of $318. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Constellation Energy options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

This Is What Whales Are Betting On Constellation Energy

Deep-pocketed investors have adopted a bullish approach towards Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in INTU usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 39 extraordinary options activities for Intuit. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 38% leaning bullish and 35% bearish. Among these notable options, 18 are puts, totaling $871,455, and 21 are calls, amounting to $1,347,324.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $670.0 to $900.0 for Intuit during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Intuit options trades today is 86.47 with a total volume of 1,024.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Intuit's big money trades within a strike price range of $670.0 to $900.0 over the last 30 days.
<h3>Intuit Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751382198_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$75.1</td>
<td>$71.1</td>
<td>$75.0</td>
<td>$740.00</td>
<td>$375.0K</td>
<td align="right">733</td>
<td align="right">50</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$164.2</td>
<td>$161.8</td>
<td>$161.8</td>
<td>$900.00</td>
<td>$97.0K</td>
<td align="right">0</td>
<td align="right">6</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$108.0</td>
<td>$105.3</td>
<td>$108.0</td>
<td>$800.00</td>
<td>$86.4K</td>
<td align="right">23</td>
<td align="right">10</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$115.3</td>
<td>$111.9</td>
<td>$115.3</td>
<td>$820.00</td>
<td>$80.7K</td>
<td align="right">15</td>
<td align="right">31</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$124.4</td>
<td>$121.3</td>
<td>$124.4</td>
<td>$800.00</td>
<td>$74.6K</td>
<td align="right">18</td>
<td align="right">35</td>
</tr>
</tbody>
</table>

<h3>About Intuit</h3>
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small business accounting and do-it-yourself tax filing in the US.
<h3>Intuit's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 300,971, the INTU's price is down by -0.81%, now at $781.23. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 51 days.</li>
</ul>
<h3>Professional Analyst Ratings for Intuit</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $880.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Intuit, targeting a price of $880. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Intuit, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

INTU

Spotlight on Intuit: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in XOM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Exxon Mobil. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $88,226, and 5 are calls, amounting to $641,400.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $105.0 to $120.0 for Exxon Mobil over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Exxon Mobil's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Exxon Mobil's substantial trades, within a strike price spectrum from $105.0 to $120.0 over the preceding 30 days.
<h3>Exxon Mobil Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751382193_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.44</td>
<td>$1.34</td>
<td>$1.37</td>
<td>$120.00</td>
<td>$411.0K</td>
<td>3.5K</td>
<td>3.0K</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.83</td>
<td>$1.68</td>
<td>$1.83</td>
<td>$115.00</td>
<td>$91.1K</td>
<td>10.6K</td>
<td>506</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/18/26</td>
<td>$10.45</td>
<td>$10.3</td>
<td>$10.3</td>
<td>$110.00</td>
<td>$85.4K</td>
<td>37</td>
<td>84</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$7.85</td>
<td>$7.5</td>
<td>$7.63</td>
<td>$115.00</td>
<td>$32.0K</td>
<td>2.2K</td>
<td>42</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$5.75</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$105.00</td>
<td>$28.8K</td>
<td>4.1K</td>
<td>65</td>
</tr>
</tbody>
</table>

<h3>About Exxon Mobil</h3>
ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil worldwide. In 2023, it produced 2.4 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At the end of 2023, reserves were 16.9 billion barrels of oil equivalent, 66% of which were liquids. The company is one of the world's largest refiners, with a total global refining capacity of 4.5 million barrels of oil per day, and is one of the world's largest manufacturers of commodity and specialty chemicals.
<h3>Where Is Exxon Mobil Standing Right Now?</h3>
<ul>
<li>With a volume of 3,297,159, the price of XOM is up 0.42% at $108.25. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 31 days.</li>
</ul>
<h3>What The Experts Say On Exxon Mobil</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $127.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Exxon Mobil, which currently sits at a price target of $127. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Exxon Mobil options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

This Is What Whales Are Betting On Exxon Mobil

Stablecoins were designed to bridge the gap between crypto and fiat, offering price stability in an otherwise volatile market. Over the past decade, they've become essential tools for traders, remittance users, and crypto-native communities. But the next chapter of their evolution isn't about us. It's about machines.
As autonomous agents and AI systems begin transacting on-chain, performing tasks, settling bills, and managing smart contracts, the limitations of today's stablecoins are becoming more apparent. If we continue designing stablecoins exclusively for human use, we risk locking the future of programmable finance into outdated constraints.
<h3 class="wp-block-heading">Today's stablecoins weren't built for autonomy</h3>
Most stablecoins in circulation today, such as USDC and USDT, are fiat-backed and centrally issued. While this has helped with mainstream adoption, it also anchors them to legacy systems—custodial reserves, regulatory chokepoints, and centralized freeze controls.
These constraints may suit traditional finance, but they're misaligned with the emerging reality of machine-to-machine (M2M) commerce. AI agents don't have bank accounts. They don't sleep. They operate in global, decentralized environments that require 24/7 access to liquid, programmable money. And they need it without relying on any human in the loop.
Even some of the newer algorithmic stablecoins have stumbled. When stability mechanisms are too complex or poorly collateralized, as seen in Terra's UST collapse, it can trigger cascading failures across ecosystems. That kind of fragility is unacceptable in autonomous systems where reliability must be engineered from the start.
<h3 class="wp-block-heading">Why machines need their own kind of money</h3>
Machine agents, whether in compute marketplaces, decentralized finance systems, or AI networks, demand a different class of stable assets. These assets must be censorship-resistant, so transactions aren't frozen unexpectedly; fully on-chain, so no off-chain issuer can break the logic, so they can interact directly with smart contracts. 
In short, the ideal currency for machines should function like an operating system primitive, trustless, programmable, and always available.
Decentralized AI marketplaces, such as those for compute and data sharing, are already operational. Autonomous agents are being trained to perform increasingly complex economic functions on-chain. And as the AI economy is estimated to surpass&nbsp; $236 billion by 2034, the need for machine-native financial rails will only grow.
The U.S. is right to pursue clarity with new bills like the GENIUS Act, but it's also playing it safe. It's creating the regulatory equivalent of a global banking app: simple, slow, and risk-averse. There's little room in that system for experimenting with programmable money or issuing decentralized, project-backed stable assets.
That's a missed opportunity. AI ecosystems are economic engines. When a decentralized project mints its own stablecoin, backed by its native token, it creates a flywheel. Users get a stable medium of exchange. The project avoids selling its token to pay expenses. The value stays in the system.&nbsp;
<h3 class="wp-block-heading">A new era of ecosystem-aligned stablecoins</h3>
There's growing interest in what could be called AI-native stablecoins, tokens designed from the ground up to support the workflows of autonomous systems. These assets are often backed by decentralized collateral, issued via smart contracts, and integrated directly into protocol-level operations.
This model transforms M2M payments into economic feedback loops. For instance, when a decentralized network issues its own stablecoin backed by its native token, it keeps value circulating internally. Contributors can be paid in stable assets. Token sell pressure decreases. The system becomes more sustainable.
It's not about replacing fiat entirely, but about unlocking a new category of programmable money that can power next-gen use cases: autonomous service provisioning, distributed compute markets, agent-to-agent data licensing, and beyond.
<h3 class="wp-block-heading">Let machines have their money</h3>
The stablecoin space has matured rapidly. But its design assumptions still orbit around human behavior, human oversight, and human needs. As we transition into a world where agents act independently—on our behalf or their own—we need to rethink those assumptions.
The future of finance isn't just peer-to-peer. It's also machine-to-machine. And if we want to keep up, we'll need stablecoins that machines can trust, use, and scale with.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Fintech news covering the emerging Financial Technology services sector

Fintech

Opinion

Why The Future Of Stablecoins Isn't Just For Humans

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $14 price target.

Price Target

Analyst Ratings

COYA

Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

Making a noteworthy insider sell on June 30, Hock E Tan, President and CEO at Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), is reported in the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001730168/000173016825000088//Archives/edgar/data/1730168/000173016825000088/0001730168-25-000088-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Tan sold 40,000 shares of Broadcom. The total transaction value is $10,731,720.
Tracking the Tuesday's morning session, Broadcom shares are trading at $266.19, showing a down of 3.43%.
<h3>Unveiling the Story Behind Broadcom</h3>
Broadcom is the sixth-largest semiconductor company globally and has expanded into various software businesses, with over $30 billion in annual revenue. It sells 17 core semiconductor product lines across wireless, networking, broadband, storage, and industrial markets. It is primarily a fabless designer but holds some manufacturing in-house, like for its best-of-breed FBAR filters that sell into the Apple iPhone. In software, it sells virtualization, infrastructure, and security software to large enterprises, financial institutions, and governments.Broadcom is the product of consolidation. Its businesses are an amalgamation of former companies like legacy Broadcom and Avago Technologies in chips, as well as Brocade, CA Technologies, and Symantec in software.
<h3>Broadcom's Financial Performance</h3>
Revenue Growth: Broadcom's remarkable performance in 3 months is evident. As of 30 April, 2025, the company achieved an impressive revenue growth rate of 20.16%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: With a high gross margin of 67.96%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Broadcom's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.05.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.97, Broadcom faces challenges in effectively managing its debt levels, indicating potential financial strain.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: A higher-than-average P/E ratio of 100.6 suggests caution, as the stock may be overvalued in the eyes of investors.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 23.33 is above industry norms, reflecting an elevated valuation for Broadcom's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 44.78, Broadcom demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001730168">Check Out The Full List Of Broadcom's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

AVGO

President and CEO At Broadcom Sells $10.73M Of Stock

Jeremy Cox, SVP at Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>), disclosed an insider sell on June 30, according to a recent SEC filing.
What Happened: Cox's recent move involves selling 68,590 shares of Hewlett Packard. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001645590/000106299325012297//Archives/edgar/data/1645590/000106299325012297/0001062993-25-012297-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value is $1,264,621.
In the Tuesday's morning session, Hewlett Packard's shares are currently trading at $20.14, experiencing a down of 1.49%.
<h3>All You Need to Know About Hewlett Packard</h3>
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure. It uses a primarily outsourced manufacturing model and employs 60,000 people worldwide.
<h3>Unraveling the Financial Story of Hewlett Packard</h3>
Positive Revenue Trend: Examining Hewlett Packard's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.87% as of 30 April, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 28.44%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Hewlett Packard's EPS is below the industry average. The company faced challenges with a current EPS of -0.82. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Hewlett Packard's debt-to-equity ratio is below the industry average. With a ratio of 0.73, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 19.66, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.86 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Hewlett Packard's EV/EBITDA ratio at 7.03 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001645590">Check Out The Full List Of Hewlett Packard's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Transaction: Jeremy Cox Sells $1.26M Worth Of Hewlett Packard Shares

GRANDE GROUP LIMITED ("GRAN" or the "Company"), a Hong Kong-based financial services provider which principally engages in the provision of corporate finance advisory services and IPO sponsor services through its Hong Kong subsidiary, Grande Capital Limited, today announced the pricing of its initial public offering (the "Offering") of 1,875,000 Class A ordinary shares (the "Class A Ordinary Shares") at the price of $5.00 per Class A Ordinary Shares (the "Offering Price").
The Class A Ordinary Shares are expected to commence trading on the Nasdaq Capital Market&nbsp;on July 1, 2025 under the ticker symbol "GRAN." The Offering is expected to close on July 2, 2025, subject to the satisfaction of customary closing conditions.
The Company expects to receive gross proceeds of approximately US$9.375 million from the Offering, before deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option (the "Over-Allotment Option") to purchase up to an additional 281,250 Class A Ordinary Shares at the Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (the "Over-allotment").&nbsp;
The Company intends to use the net proceeds from the Offering for strengthening the corporate finance advisory business, developing the asset management business, establishing equity capital market services, and general working capital purposes.

IPOs

GRAN

Grande Group Limited Announces Pricing Of ~$9.375M Initial Public Offering Of 1.875M Class A Shares At A Price Of $5/Share

It was reported on July 1, that Christopher Harborne, 10% Owner at Innovative Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISSC#NASDAQ">ISSC</a>) executed a significant insider sell, according to an SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000836690/000194647925000025//Archives/edgar/data/836690/000194647925000025/0001946479-25-000025-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that Harborne executed a sale of 217,508 shares of Innovative Solns with a total value of $2,976,517.
The latest update on Tuesday morning shows Innovative Solns shares down by 0.58%, trading at $13.8.
<h3>All You Need to Know About Innovative Solns</h3>
Innovative Solutions and Support Inc is a systems integrator that designs, manufactures, sells, and services air data equipment, engine display systems, standby equipment, primary flight guidance, and cockpit display systems for retrofit applications and original equipment manufacturers. The company supplies integrated Flight Management Systems, Flat Panel Display Systems, Integrated Standby Units, Positioning System receivers that enable reduced carbon footprint navigation, and an Autothrottle, which allows a pilot to automatically control the power setting of the engine and is designed to reduce pilot workload and enhance safety. It sells its products to both the OEM and the retrofit markets.
<h3>Financial Insights: Innovative Solns</h3>
Revenue Growth: Innovative Solns displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 104.26%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 51.36%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Innovative Solns's EPS reflects a decline, falling below the industry average with a current EPS of 0.3.
</li>
</ul>
Debt Management: Innovative Solns's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.51, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: Innovative Solns's P/E ratio of 22.76 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 3.75 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 15.05, Innovative Solns could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000836690">Check Out The Full List Of Innovative Solns's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISSC

10% Owner Of Innovative Solns Sold $2.98M In Stock

A significant insider transaction involving the exercise of company stock options was reported on June 30, by Cameron M Bready, Chief Executive Officer at Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>), as per the latest SEC filing.
What Happened: In an insider options sale disclosed in a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001123360/000112760225018220//Archives/edgar/data/1123360/000112760225018220/0001127602-25-018220-index.htm">U.S. Securities and Exchange Commission</a>, Bready, Chief Executive Officer at Global Payments, exercised stock options for 3,780 shares of GPN. The transaction value amounted to $94,840.
Currently, Global Payments shares are trading down 0.05%, priced at $80.0 during Tuesday's morning. This values Bready's 3,780 shares at $94,840.
<h3>About Global Payments</h3>
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.
<h3>Global Payments's Economic Impact: An Analysis</h3>
Revenue Challenges: Global Payments's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -0.33%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: With a high gross margin of 61.81%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Global Payments's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.24.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.76.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Global Payments's P/E ratio of 12.95 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 2.0, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 7.66, Global Payments presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001123360">Check Out The Full List Of Global Payments's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Major Decision: Cameron M Bready Exercises Options, Realizing $94K At Global Payments

In a new SEC filing on June 30, it was revealed that POLK, Hyve Solutions Executive at TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>), executed a significant exercise of company stock options.
What Happened: A notable Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001177394/000112760225018222//Archives/edgar/data/1177394/000112760225018222/0001127602-25-018222-index.htm">U.S. Securities and Exchange Commission</a> revealed that POLK, Hyve Solutions Executive at TD Synnex, exercised stock options for 14,250 shares of SNX, resulting in a transaction value of $631,275.
TD Synnex shares are trading down 0.65% at $134.82 at the time of this writing on Tuesday morning. Since the current price is $134.82, this makes POLK's 14,250 shares worth $631,275.
<h3>Unveiling the Story Behind TD Synnex</h3>
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
<h3>TD Synnex: Financial Performance Dissected</h3>
Positive Revenue Trend: Examining TD Synnex's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.85% as of 31 May, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 7.0%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): TD Synnex's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.22.
</li>
</ul>
Debt Management: TD Synnex's debt-to-equity ratio is below the industry average at 0.49, reflecting a lower dependency on debt financing and a more conservative financial approach.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.89 is lower than the industry average, implying a discounted valuation for TD Synnex's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.19 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 8.71, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001177394">Check Out The Full List Of TD Synnex's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DENNIS POLK At TD Synnex Executes Options Exercise, Realizing $631K

On June 30, it was revealed in an SEC filing that RICHARD HUME, Director at TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) executed a significant exercise of company stock options.
What Happened: HUME, Director at TD Synnex, exercised stock options for 63,310 shares of SNX stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001177394/000112760225018226//Archives/edgar/data/1177394/000112760225018226/0001127602-25-018226-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The exercise price of the options was $87.82 per share.
TD Synnex shares are trading down 0.0% at $135.7 at the time of this writing on Tuesday morning. Since the current price is $135.7, this makes HUME's 63,310 shares worth $3,031,282.
<h3>Get to Know TD Synnex Better</h3>
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
<h3>TD Synnex: A Financial Overview</h3>
Positive Revenue Trend: Examining TD Synnex's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.85% as of 31 May, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 7.0%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): TD Synnex's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 2.22.
</li>
</ul>
Debt Management: TD Synnex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: TD Synnex's P/E ratio of 15.89 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.19, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 8.71, TD Synnex presents an attractive value opportunity.
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001177394">Check Out The Full List Of TD Synnex's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Major Decision: RICHARD HUME Exercises Options, Realizing $3.03M At TD Synnex

A notable acquisition unfolded on June 30, as Mazzacco, Director at Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>), reported the acquisition of stock options for 5,000 shares in an SEC filing.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001711279/000196772225000002//Archives/edgar/data/1711279/000196772225000002/0001967722-25-000002-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Mazzacco, Director at Krystal Biotech, acquired 5,000 stock options for KRYS with an exercise price of $137.46 per share.
Krystal Biotech shares are currently trading up by 0.9%, with a current price of $138.7 as of Tuesday morning. This brings the total value of Mazzacco's 5,000 shares to $6,199.
<h3>All You Need to Know About Krystal Biotech</h3>
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
<h3>Breaking Down Krystal Biotech's Financial Performance</h3>
Revenue Growth: Krystal Biotech displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 94.88%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 94.3%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 1.24, Krystal Biotech showcases strong earnings per share.
</li>
</ul>
Debt Management: Krystal Biotech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 32.96 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 12.32 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 23.99, Krystal Biotech presents an attractive value opportunity.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001711279">Check Out The Full List Of Krystal Biotech's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

Catherine Mazzacco Takes A Bullish Stance, Acquiring Krystal Biotech Stock Options Worth $6K

Dino A Rossi, Board Member at Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>), reported acquisition of company stock options on June 30, according to a new SEC filing.
What Happened: Revealed in a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001711279/000120905925000003//Archives/edgar/data/1711279/000120905925000003/0001209059-25-000003-index.htm">U.S. Securities and Exchange Commission</a>, Rossi, Board Member at Krystal Biotech, strategically acquired stock options for 5,000 shares of KRYS. These options empower Rossi to buy the company's stock at a favorable exercise price of $137.46 per share.
The Tuesday morning market activity shows Krystal Biotech shares up by 0.9%, trading at $138.7. This implies a total value of $6,199 for Rossi's 5,000 shares.
<h3>All You Need to Know About Krystal Biotech</h3>
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
<h3>Understanding the Numbers: Krystal Biotech's Finances</h3>
Revenue Growth: Krystal Biotech displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 94.88%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 94.3%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Krystal Biotech's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.24.
</li>
</ul>
Debt Management: Krystal Biotech's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 32.96 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 12.32, Krystal Biotech's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 23.99 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001711279">Check Out The Full List Of Krystal Biotech's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dino A Rossi Exhibits Confidence With An Acquisition Of Krystal Biotech Stock Options Worth $6K

A substantial insider activity was disclosed on June 30, as Mason, Board Member at Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>), reported the exercise of a large sell of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001711279/000183644025000003//Archives/edgar/data/1711279/000183644025000003/0001836440-25-000003-index.htm">U.S. Securities and Exchange Commission</a>, Mason, Board Member at Krystal Biotech, exercised stock options for 0 shares of KRYS. The transaction value amounted to $0.
Currently, Krystal Biotech shares are trading down 0.0%, priced at $137.46 during Tuesday's morning. This values Mason's 0 shares at $0.
<h3>Unveiling the Story Behind Krystal Biotech</h3>
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
<h3>Understanding the Numbers: Krystal Biotech's Finances</h3>
Revenue Growth: Krystal Biotech's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 94.88%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: With a high gross margin of 94.3%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Krystal Biotech's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.24.
</li>
</ul>
Debt Management: Krystal Biotech's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 32.96 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 12.32, Krystal Biotech's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 23.99, Krystal Biotech presents an attractive value opportunity.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes To Focus On</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001711279">Check Out The Full List Of Krystal Biotech's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision Unfolding At Krystal Biotech: Christopher Mason Exercises Options, Resulting In $0

Highlighted on June 30, it was unveiled in an SEC filing that Janney, Director at Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>), executed a significant transaction involving the exercise of company stock options.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001711279/000171127925000057//Archives/edgar/data/1711279/000171127925000057/0001711279-25-000057-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that Janney, Director at Krystal Biotech, a company in the Health Care sector, just exercised stock options worth 0 shares of KRYS stock with an exercise price of $0.0.
Krystal Biotech shares are trading, exhibiting down of 0.0% and priced at $137.46 during Tuesday's morning. This values Janney's 0 shares at $0.
<h3>All You Need to Know About Krystal Biotech</h3>
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
<h3>Key Indicators: Krystal Biotech's Financial Health</h3>
Revenue Growth: Over the 3 months period, Krystal Biotech showcased positive performance, achieving a revenue growth rate of 94.88% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Insights into Profitability:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 94.3%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Krystal Biotech's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.24.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.01, Krystal Biotech adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 32.96 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 12.32 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 23.99 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001711279">Check Out The Full List Of Krystal Biotech's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Notable Insider Move: Daniel Janney Takes Part In Options Exercise At Krystal Biotech, Resulting In $0

WIIM

MAIA

MAIA Biotechnology shares are trading higher. The company announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies 2025 Congress.

A large exercise of company stock options by Everett Rand Sutherland, Board Member at Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) was disclosed in a new SEC filing on June 30, as part of an insider exercise.
What Happened: Disclosed in a Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0001711279/000185288025000003//Archives/edgar/data/1711279/000185288025000003/0001852880-25-000003-index.htm">U.S. Securities and Exchange Commission</a>, Sutherland, Board Member at Krystal Biotech, executed a strategic derivative sale. This involved exercising stock options for 0 shares of KRYS, resulting in a transaction value of $0.
Krystal Biotech shares are currently trading down by 0.0%, with a current price of $137.46 as of Tuesday morning. This brings the total value of Sutherland's 0 shares to $0.
<h3>About Krystal Biotech</h3>
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
<h3>Krystal Biotech's Economic Impact: An Analysis</h3>
Revenue Growth: Over the 3 months period, Krystal Biotech showcased positive performance, achieving a revenue growth rate of 94.88% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 94.3%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Krystal Biotech's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 1.24.
</li>
</ul>
Debt Management: Krystal Biotech's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 32.96 is lower than the industry average, implying a discounted valuation for Krystal Biotech's stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 12.32 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 23.99, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001711279">Check Out The Full List Of Krystal Biotech's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Update: Everett Rand Sutherland Engages In Options Exercise At Krystal Biotech Realizing $0

Legal

Press Releases

HIMS LAWSUIT DEADLINE: Suffer Losses on Hims & Hers Health, Inc.? Contact BFA Law before the August 25 Securities Fraud Class Action Deadline (NYSE:HIMS)

Deadline Approaching: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith

HIMS & HERS HEALTH, INC. (NYSE: HIMS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Hims & Hers Health, Inc. Investors of Upcoming Deadline

Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy®– Hagens Berman

HIMS Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed

HIMS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS

HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Hims & Hers Health, Inc. Lawsuit - HIMS

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hinge Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Hldgs

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

Omada Health

Option Care Health

OPKO Health

Premier

Pennant Gr

Privia Health Gr

RadNet

GeneDx Holdings Corp. - Class A Common Stock

Comments

Hims & Hers Health

ニュース

最新ニュース Hims & Hers Health (NYSE:HIMS) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル